StreetInsider.com News Articles

LB Pharmaceuticals to Participate in Upcoming Investor Events

Thu, 15 Oct 2026 16:05:00 -0400

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:

Craig-Hallum Biotech Catalyst Conference

Virtual fireside chat at 10:00 a.m. ET and virtual 1x1 investor meetings on Thursday, October 22, 2026

Guggenheim

LB Pharmaceuticals to Participate in Upcoming Investor Events

Thu, 15 Oct 2026 16:05:00 -0400

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:

Craig-Hallum Biotech Catalyst Conference

Virtual fireside chat at 10:00 a.m. ET and virtual 1x1 investor meetings on Thursday, October 22, 2026

Guggenheim

Form 4 LB PHARMACEUTICALS INC For: Oct 09 Filed by: Miller Joseph M

Tue, 13 Oct 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20261013/27181201.html

Form 4 LB PHARMACEUTICALS INC For: Oct 09 Filed by: Kozauer Susan Gani

Tue, 13 Oct 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20261013/27181202.html

Form SCHEDULE 13G/A LB PHARMACEUTICALS INC Filed by: JPMORGAN CHASE & CO

Tue, 13 Oct 2026 13:46:00 -0400
si-local-file:///var/storage/secattach/20261013/27180438.html

H.C. Wainwright Reiterates Buy Rating on LB Pharmaceuticals Inc (LBRX)

Mon, 12 Oct 2026 06:53:56 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $60.00 price target on LB Pharmaceuticals Inc (NASDAQ: LBRX).
The analyst commented: "Late last week, LB Pharmaceuticals reported the presentation of four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026 in Munich, Germany. The posters highlight new preclinical data describing the company's lead candidate LB-102’s differentiated mechanism of action; the pivotal program for this compound in schizophrenia (NOVA-2 and NOVA-3); the ongoing late-stage development of LB-102 in bipolar depression (ILLUMINATE-1); and a previously reported analysis of LB-102’s impact on cognitive performance from the Phase

Guggenheim Reiterates Buy Rating on LB Pharmaceuticals Inc (LBRX)

Mon, 12 Oct 2026 06:11:53 -0400

Guggenheim analyst Delma Caiati reiterated a Buy rating and $80.00 price target on LB Pharmaceuticals Inc (NASDAQ: LBRX).
The analyst commented: "A new microdialysis study, presented by LBRX over the weekend at ECNP congress, provides the first direct functional evidence that orally administered LB-102 (novel benzamide D2/D3/5-HT7 receptor antagonist) engages presynaptic dopamine D2/D3 autoreceptors in the rat nucleus accumbens — the circuit governing reward and motivation, and the node implicated in anhedonia. This matters for three reasons: (1) It confirms that oral low-dose LB-102 reaches and acts at its intended presynaptic target — the mechanistic premise of the bimodal dose thesis

LB Pharmaceuticals presents LB-102 data at ECNP congress

Sat, 10 Oct 2026 08:00:16 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) presented four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress in Munich, Germany, on Oct. 10, 2026, according to a company press release.

The presentations included new preclinical data on LB-102's mechanism of action, updates on the Phase 3 NOVA-2 and NOVA-3 trials in schizophrenia, the ongoing Phase 2 ILLUMINATE-1 trial in bipolar depression, and a previously reported analysis of cognitive performance data from the Phase 2 NOVA-1 schizophrenia trial.

One poster described preclinical findings showing that LB-102 modulates dopamine signaling through pre-synaptic D2 autoreceptors, increasing dopamine neurotransmission in a brain region associated with schizophrenia

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

Sat, 10 Oct 2026 08:00:00 -0400

NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the presentation of four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place in Munich, Germany from October 10-13, 2026. The posters highlight new preclinical data describing LB-102’s differentiated mechanism of action, the pivotal program of LB-102 in schizophrenia (NOVA-2 and NOVA-3), the ongoing late-stage development of LB-102 in bipolar depression (ILLUMINATE-1), and a previously

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

Sat, 10 Oct 2026 08:00:00 -0400

NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the presentation of four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place in Munich, Germany from October 10-13, 2026. The posters highlight new preclinical data describing LB-102’s differentiated mechanism of action, the pivotal program of LB-102 in schizophrenia (NOVA-2 and NOVA-3), the ongoing late-stage development of LB-102 in bipolar depression (ILLUMINATE-1), and a previously

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 09 Oct 2026 16:42:00 -0400

NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the “inducement

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 09 Oct 2026 16:42:00 -0400

NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the “inducement

Canaccord Starts LB Pharmaceuticals Inc (LBRX) at Buy

Fri, 09 Oct 2026 05:06:04 -0400

Canaccord analyst Sumant Kulkami initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Buy rating and a price target of $65.00.
For an analyst ratings summary and ratings history on LB Pharmaceuticals Inc click here. For more ratings news on LB Pharmaceuticals Inc click here.
Shares of LB Pharmaceuticals Inc closed at $34.61 yesterday.

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

Tue, 06 Oct 2026 08:00:00 -0400

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. The event will feature Roger S. McIntyre, MD, FRCPC (University of Toronto), alongside LB management team members Heather Turner (CEO), Susan G. Kozauer (CMO), Kaya Pai Panandiker (CCO), Gad Soffer (COBO), and

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

Tue, 06 Oct 2026 08:00:00 -0400

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. The event will feature Roger S. McIntyre, MD, FRCPC (University of Toronto), alongside LB management team members Heather Turner (CEO), Susan G. Kozauer (CMO), Kaya Pai Panandiker (CCO), Gad Soffer (COBO), and

Form EFFECT LB PHARMACEUTICALS INC

Tue, 06 Oct 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20261006/27151362.html

Guggenheim Starts LB Pharmaceuticals Inc (LBRX) at Buy

Mon, 05 Oct 2026 16:07:07 -0400

Guggenheim analyst Delma Caiati initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Buy rating and a price target of $80.00.

For an analyst ratings summary and ratings history on LB Pharmaceuticals Inc click here. For more ratings news on LB Pharmaceuticals Inc click here.

Shares of LB Pharmaceuticals Inc closed at $36.99 yesterday.

Roth/MKM Downgrades LB Pharmaceuticals Inc (LBRX) to Neutral

Mon, 05 Oct 2026 08:54:40 -0400

Roth/MKM analyst Boobalan Pachaiyappan downgraded LB Pharmaceuticals Inc (NASDAQ: LBRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on LB Pharmaceuticals Inc click here. For more ratings news on LB Pharmaceuticals Inc click here.
Shares of LB Pharmaceuticals Inc closed at $36.99 yesterday.

Needham Starts LB Pharmaceuticals Inc (LBRX) at Buy

Fri, 02 Oct 2026 04:36:21 -0400

Needham analyst Ami Fadia initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Buy rating and a price target of $68.00.
The analyst comments: “We initiate coverage on LBRX with a Buy rating and $68 PT with the following investment thesis: (1) LB-102, is an improved version of amisulpride, one of the most effective antipsychotics OUS, and de-risked based on extensive data, (2) NOVA-1 data in schizophrenia supported best in-class efficacy and safety (EPS, sedation and QTc typically limit D2 agents); weight gain likely modest and self-limiting based on amisulpride's experience, (3) Bimodal mechanism supports multiple indications (e.g., BPD, adj.

Needham Starts LB Pharmaceuticals Inc (LBRX) at Buy

Fri, 02 Oct 2026 04:36:21 -0400

Needham analyst Ami Fadia initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Buy rating and a price target of $68.00.
The analyst comments: “We initiate coverage on LBRX with a Buy rating and $68 PT with the following investment thesis: (1) LB-102, is an improved version of amisulpride, one of the most effective antipsychotics OUS, and de-risked based on extensive data, (2) NOVA-1 data in schizophrenia supported best in-class efficacy and safety (EPS, sedation and QTc typically limit D2 agents); weight gain likely modest and self-limiting based on amisulpride's experience, (3) Bimodal mechanism supports multiple indications (e.g., BPD, adj.

Form POS AM LB PHARMACEUTICALS INC

Thu, 01 Oct 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20261001/27135984.html

Form S-3ASR LB PHARMACEUTICALS INC

Thu, 01 Oct 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20261001/27135928.html

Form 3 LB PHARMACEUTICALS INC For: Sep 14 Filed by: Kozauer Susan Gani

Thu, 24 Sep 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260924/27102518.html

Form 424B3 LB PHARMACEUTICALS INC

Tue, 15 Sep 2026 08:22:00 -0400
si-local-file:///var/storage/secattach/20260915/27061632.html

Form 8-K LB PHARMACEUTICALS INC For: Sep 15

Tue, 15 Sep 2026 08:05:00 -0400
si-local-file:///var/storage/secattach/20260915/27061540.html